PDGFRA and gastrointestinal stromal tumor: Study 1002 was a retrospective, observational, chart-based natural history study that evaluated the response and survival of patients with unresectable/metastatic PDGFRA D842V-mutant GIST treated during their clinical course with TKIs other than avapritinib [20].